Best-in-class - Optimized treatment of hypertension and heart failure

QGC006 and QGC606, “best-in-class” future products

The company plans to strengthen its pipeline by developing a second generation products to manage the life cycle of BAPAI technology products. The objective of this program is to identify within this new class a back-up product of the firibastat that could become a “Best in Class” product.

Quantum Genomics has selected QGC006, which is ten times more potent than firibastat in inhibiting the activity of Aminopeptidase A and QGC606 which is a novel prodrug of a potent aminopeptidase A inhibitor.